There's a lot of action in the company's pipeline, which investors are taking time to digest.
News & Analysis: Fate Therapeutics
FATE earnings call for the period ending September 30, 2019.
FATE earnings call for the period ending June 30, 2019.
The immune cells live up to their name in natural settings, but engineered therapies have delivered mixed results in clinical trials.
FATE earnings call for the period ending March 31, 2019.
FATE earnings call for the period ending December 31, 2018.
These small biotech stocks are red-hot. But can they keep the momentum going?
Can the momentum continue for these hot biotech stocks?
Make that two consecutive days of riding the momentum from the Juno Therapeutics acquisition.